Ferring commits further to Antares devices:
This article was originally published in Clinica
Ferring Pharmaceuticals of Denmark has expanded its partnership with Antares Pharma covering the latter's needle-free delivery devices. Ferring already markets the Exton, Pennsylvania firm's Medi-Jector Vision device for use with the growth hormone product, Zomacton. It now plans to access newer versions of Antares' devices at a cost of E1.5m ($1.6m). The currently marketed product, branded Zomajet 2 Vision, is a reusable spring-loaded device that loads the drug from a vial and delivers it as a fine liquid stream.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.